latest news releases from the newsroom
Tekron, Inc. Announces the Retaining of The Wall Street Organization, Inc. Tuesday, July 22, 2003
FORT LAUDERDALE, Fla., July 22, 2003 (PRIMEZONE) -- Tekron, Inc. (OTCBB:TKRN) today announced that it has retained the investment banking services of The Wall Street Organization, Inc. (WSO). The Wall Street Organization, Inc., www.wallstreetorganization.com, is a global state-of-the-art, on-line Investment Banking firm specializing in mergers, acquisitions and financial public relations for both public and private companies. According to the Company's CEO, Stephen M. Cole, "WSO is excited about being selected to tell the Tekron story, which will include the employment of a variety of new proprietary methodologies."
FindProfit.com Provides Earnings Preview for Select Portfolio Stocks
PRINCETON, N.J., July 22, 2003 (PRIMEZONE) -- FindProfit (www.findprofit.com), an investment advisory service that delivered a +73% audited return in 2002, announced today that it has provided to trial and paid subscribers a "what to look for" earnings preview on several of FindProfit's portfolio stocks which are reporting financial results this week. Two of the profiled stocks include AOL Time Warner (NYSE:AOL) and Activision (Nasdaq:ATVI).
Blyth, Inc. Estimates Second Quarter E.P.S.
GREENWICH, Conn., July 22, 2003 (PRIMEZONE) -- Blyth, Inc. (NYSE:BTH) (the "Company"), a worldwide leader in the home expressions marketplace, today announced that second quarter fiscal year 2004 earnings are anticipated to be below prior year and management's initial expectations across most of its business units and distribution channels in North America and Europe, reflecting weak economic conditions, as well as consumer and retailer caution, in its major markets. The Company's financial results for the quarter ending July 31, 2003 will be announced on August 27, 2003. Second quarter Earnings Per Share are expected to be $0.20 - $0.24. Earnings Per Share for the second quarter of fiscal year 2003 were $0.40.
Insert Therapeutics, Inc.
Insert Therapeutics Describes In Vivo Performance and Versatility of Drug Delivery Platform
PASADENA, Calif., Jul 22, 2003 (PRIMEZONE) -- Insert Therapeutics, Inc. President and Chief Executive Officer, Leonard R. Borrmann, Pharm.D., presented data today demonstrating the flexibility and distinct advantages of the company's proprietary Cyclosert(tm) drug delivery technology. First, Cyclosert provides a solution to the diverse challenges of systemic delivery for small-molecule drugs that, without delivery enhancement, have limited clinical effectiveness or unacceptable toxicity. Second, Cyclosert can be used to formulate, protect and systemically deliver nucleic acids, including plasmid DNA, RNA and oligonucleotides, into targeted cells with subsequent expression.